Interobserver variability in the radiological assessment of response to chemotherapy in glioma
- PMID: 12629241
- DOI: 10.1212/01.wnl.0000049467.54667.92
Interobserver variability in the radiological assessment of response to chemotherapy in glioma
Abstract
Objective: To assess the interobserver variability in the radiologic assessment of response to chemotherapy in patients with recurrent glioma.
Methods: Five clinicians with experience in the treatment and follow-up of patients with glioma measured tumor size in 20 pairs of CT and 20 pairs of MRI scans of 35 patients who had been treated with chemotherapy for recurrent glioma. Tumor size was defined as the product of the two largest perpendicular enhancing tumor diameters on the postcontrast images. To assess the interobserver variability in the measurements of tumor size, and in the classification according to the widely used Macdonald response criteria, intraclass correlation coefficients (ICC) and weighted kappa values were calculated.
Results: Substantial interobserver agreement was noted in the manual, two-dimensional measurements of tumor size on CT and MRI in patients treated with chemotherapy for recurrent glioma (overall ICC 0.64). Classification of response to chemotherapy according to the Macdonald criteria resulted in moderate interobserver agreement (overall weighted kappa 0.51). In 65% of evaluated CT and in 55% of evaluated MRI studies, no complete consensus was found for the categorical tumor response measurement.
Conclusion: The radiologic assessment of response to chemotherapy in patients with recurrent glioma is susceptible to considerable interobserver variability. This underlines the difficulties that arise in scoring response to chemotherapy by conventional radiologic techniques.
Similar articles
-
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.Ann Oncol. 2003 Apr;14(4):599-602. doi: 10.1093/annonc/mdg157. Ann Oncol. 2003. PMID: 12649108 Clinical Trial.
-
Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.Cancer. 2004 Feb 15;100(4):807-13. doi: 10.1002/cncr.20042. Cancer. 2004. PMID: 14770438 Clinical Trial.
-
Bevacizumab is active as a single agent against recurrent malignant gliomas.Anticancer Res. 2010 Feb;30(2):609-11. Anticancer Res. 2010. PMID: 20332478
-
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.Neurology. 2004 Aug 10;63(3):535-7. doi: 10.1212/01.wnl.0000133398.11870.9a. Neurology. 2004. PMID: 15304589 Review.
-
Aggressive oligodendroglioma: a chemosensitive tumor.Recent Results Cancer Res. 1994;135:127-33. doi: 10.1007/978-3-642-85039-4_13. Recent Results Cancer Res. 1994. PMID: 8047688 Review. No abstract available.
Cited by
-
Response criteria for glioma.Nat Clin Pract Oncol. 2008 Nov;5(11):634-44. doi: 10.1038/ncponc1204. Epub 2008 Aug 19. Nat Clin Pract Oncol. 2008. PMID: 18711427 Free PMC article. Review.
-
Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma.Oncologist. 2014 Aug;19(8):790-6. doi: 10.1634/theoncologist.2014-0003. Epub 2014 Jul 7. Oncologist. 2014. PMID: 25001266 Free PMC article. Clinical Trial.
-
High resolution ultra high field magnetic resonance imaging of glioma microvascularity and hypoxia using ultra-small particles of iron oxide.Invest Radiol. 2009 Jul;44(7):375-83. doi: 10.1097/RLI.0b013e3181a8afea. Invest Radiol. 2009. PMID: 19448552 Free PMC article.
-
Interrater reliability of Brain Tumor Reporting and Data System (BT-RADS) in the follow up of adult primary brain tumors: a single institution experience in Italy.Quant Imaging Med Surg. 2023 Nov 1;13(11):7423-7431. doi: 10.21037/qims-22-850. Epub 2023 Jan 14. Quant Imaging Med Surg. 2023. PMID: 37969622 Free PMC article.
-
Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).J Neurooncol. 2004 Dec;70(3):359-69. doi: 10.1007/s11060-004-9175-1. J Neurooncol. 2004. PMID: 15662978 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical